Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 4/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | CBR1 | P16152 | 1/20 | 0.33 |
| ▸ | DNM2 | P50570 | 1/20 | 0.33 |
| ▸ | GAPDH | P04406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20378613 | 1.00 | MAOA (0.37) | MAOAMAOBLCKADORA2AADORA1 | |
| SCHEMBL18173633 | 0.86 | ALDH1A1 (0.41) | ADORA2AADORA1ADORA3CA12CA1 | |
| SCHEMBL20378630 | 0.86 | ALDH1A1 (0.41) | ADORA2AADORA1ADORA3CA12CA1 | |
| SCHEMBL20383962 | 0.80 | LOXL2 (0.36) | ADORA2AADORA1ADORA3CA12CA1 | |
| SCHEMBL20378523 | 0.79 | BACE1 (0.33) | ADORA2AADORA1ADORA3CA12CA1 | |
| SCHEMBL18180649 | 0.79 | BACE1 (0.33) | ADORA2AADORA1ADORA3CA12CA1 | |
| SCHEMBL7570679 | 0.73 | ALDH1A1 (0.33) | AR | |
| SCHEMBL7561115 | 0.72 | CYP19A1 (0.32) | — | |
| SCHEMBL14105295 | 0.72 | CYP19A1 (0.32) | — | |
| SCHEMBL18173611 | 0.71 | CA12 (0.43) | ADORA2AADORA1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2018-07-19 | — | — | US | claimed |
| EP-3250035-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | Allgenesis Biotherapeutics Inc. (TW) | 2017-12-06 | — | — | EP | claimed |
| WO-2016172255-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2016-10-27 | — | — | WO | claimed |
| US-10870635-B2 | Compounds and their use as BACE1 inhibitors | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2020-12-22 | — | — | US | disclosed |
| US-10870635-B2 | Compounds and their use as BACE1 inhibitors | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2020-12-22 | — | — | US | disclosed |
| CN-107613771-B | Compounds and their use as beta-secretase 1 inhibitors | 新源生物科技股份有限公司 | 2020-12-15 | — | — | CN | disclosed |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2018-07-19 | — | — | US | disclosed |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2018-07-19 | — | — | US | disclosed |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2018-07-19 | — | — | US | disclosed |
| EP-3250035-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | Allgenesis Biotherapeutics Inc. (TW) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016172255-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016172255-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS, INC. (TW) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870635-B2 | Compounds and their use as BACE1 inhibitors | BACE1, BACE2, APP | MAOA 732/4885MAOB 442/4885LCK 1263/4885 |
| US-20180201604-A1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | BACE1, BACE2, APP | MAOA 666/4885MAOB 365/4885LCK 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.